Physician profile
Lech Dabrowski
NPI 1780798553
$13,279.04
in general payments reported to CMS, 2019-2025
55 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,194 · 2020: $1,286 · 2021: $3,537 · 2022: $5,262.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $2,139.12 | 2021-2022 | |
| Janssen Biotech, INC. | $1,301.21 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,039.74 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $886.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $725.80 | 2019-2022 | |
| Astellas Pharma US INC | $626.06 | 2019-2022 | |
| Lilly USA, LLC | $552.10 | 2019-2022 | |
| Amgen INC. | $479.06 | 2019-2022 | |
| Celgene Corporation | $465.54 | 2019-2022 | |
| Incyte Corporation | $398.72 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $344.45 | 2019-2022 | |
| Genzyme Corporation | $333.80 | 2020-2022 | |
| Daiichi Sankyo INC. | $325.38 | 2019-2022 | |
| Genentech USA, INC. | $319.68 | 2019-2020 | |
| Pfizer INC. | $314.68 | 2019-2022 |
Show all 55 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lech Dabrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.